Antiviral Drugs - Czechia | Statista Market Forecast

In Czechia, the revenue in the Antiviral Drugs market is estimated to reach US$84.21m by 2024.
The market is expected to experience a compound annual growth rate (CAGR 2024-2029) of 1.79%, leading to a market volume of US$92.03m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, reaching US$30.64bn in 2024.
Czechia's antiviral drug market is witnessing a surge in demand due to the country's proactive approach towards public health.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

Antiviral drugs have gained significant attention in recent times due to the global outbreak of COVID-19. In Czechia, the antiviral drugs market has witnessed steady growth in recent years.

Customer preferences: The demand for antiviral drugs in Czechia is driven by the increasing prevalence of viral infections. The country has a high incidence of hepatitis C and B, which has led to an increase in the demand for antiviral drugs. Additionally, the COVID-19 pandemic has further boosted the demand for antiviral drugs in the country.

Trends in the market: One of the significant trends in the antiviral drugs market in Czechia is the increasing adoption of generic antiviral drugs. The government's efforts to reduce healthcare costs have led to the promotion of generic drugs, which are cheaper than branded drugs. This has resulted in an increase in the availability of affordable antiviral drugs for patients.Another trend in the market is the increasing focus on research and development of new antiviral drugs. Several pharmaceutical companies are investing in the development of new antiviral drugs that are more effective and have fewer side effects. This is expected to drive the growth of the antiviral drugs market in the country.

Local special circumstances: The Czech government has implemented several measures to promote the use of generic drugs. The government has set a limit on the prices of drugs, which has resulted in a decrease in the prices of generic drugs. Additionally, the government has also introduced a system of reference pricing, which has further reduced the prices of drugs.

Underlying macroeconomic factors: The Czech Republic has a well-developed healthcare system, which has contributed to the growth of the antiviral drugs market. The country has a high standard of living, and the population has access to quality healthcare services. Additionally, the country has a strong pharmaceutical industry, which has contributed to the development and availability of antiviral drugs.In conclusion, the antiviral drugs market in Czechia is expected to witness significant growth in the coming years. The increasing prevalence of viral infections, the promotion of generic drugs, and the focus on research and development of new antiviral drugs are expected to drive the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.